NAD Nicoderm CQ ad decision being appealed to NARB by SmithKline Beecham.
This article was originally published in The Tan Sheet
Executive Summary
NAD NICODERM CQ AD DECISION APPEALED BY SMITHKLINE BEECHAM to the National Advertising Review Board, according to a NAD Case Report issued June 12. The firm disagrees with the decision of the National Advertising Division of the Council of Better Business Bureaus that its comparative advertising for Consumer Products' Nicoderm CQ nicotine replacement patches inaccurately communicates dose strengths and treatment lengths of the products being compared and should be modified. SmithKline Beecham believes NAD's solution would create confusion among consumers and asked that an NARB panel be convened to "review the truthfulness and accuracy of the advertisement at issue."